Clinical Trial Update: A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rivaroxaban to reduce death, myocardial infarction, or stroke in heart failure patients with coronary artery disease after decompensati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Heart Failure

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Heart Failure, Coronary Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-05-10